Cumberland pharmaceuticals reports annual 2023 financial results

2023 highlights include expanded fda approval and new study publications nashville, tenn. , march 5, 2024 /prnewswire/ -- cumberland pharmaceuticals inc. (nasdaq: cpix), a specialty pharmaceutical company, announced today that its product portfolio of fda-approved brands delivered combined revenues of $40 million in 2023 and provided $6 million in cash generated from operations.
CPIX Ratings Summary
CPIX Quant Ranking